Cellectar Biosciences CLRB shares are trading higher on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating and $5 price target.
Cellectar Biosciences is a clinical stage biopharmaceutical company. It focuses on development of targeted phospholipid drug conjugates for the treatment and imaging of cancer.
The company's pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic phospholipid drug conjugates. Its portfolio of products in development includes CLR 131, CTX Product Portfolio consisting of CTX CLR 1800-P, CTX CLR 1602-PTX and CTX CLR 1700, CLR 125, CLR 124 and CLR 1502.
Cellectar Biosciences shares were trading up 9.44% at $1.40 at the time of publication on Wednesday. The stock has a 52-week high of $3.33 and a 52-week low of $1.01.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
